Cargando…

Hepatitis C virus treatment response to ledipasvir/sofosbuvir among patients coinfected with HIV and HCV: Real world data in a black population

Treatment of hepatitis C virus (HCV) infection for patients with human immunodeficiency virus (HIV) has improved with direct acting antivirals. However, outcomes among Black persons treated with ledipasvir/sofosbuvir (LDV/SOF) may be inferior to non-Blacks. We assessed responses to LDV/SOF in a coho...

Descripción completa

Detalles Bibliográficos
Autores principales: Banga, Jaspreet, Nizami, Sobia, Slim, Jihad, Nagarakanti, Sandhya, Portilla, Mario, Swaminathan, Shobha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7440318/
https://www.ncbi.nlm.nih.gov/pubmed/32176039
http://dx.doi.org/10.1097/MD.0000000000019140
_version_ 1783573147633582080
author Banga, Jaspreet
Nizami, Sobia
Slim, Jihad
Nagarakanti, Sandhya
Portilla, Mario
Swaminathan, Shobha
author_facet Banga, Jaspreet
Nizami, Sobia
Slim, Jihad
Nagarakanti, Sandhya
Portilla, Mario
Swaminathan, Shobha
author_sort Banga, Jaspreet
collection PubMed
description Treatment of hepatitis C virus (HCV) infection for patients with human immunodeficiency virus (HIV) has improved with direct acting antivirals. However, outcomes among Black persons treated with ledipasvir/sofosbuvir (LDV/SOF) may be inferior to non-Blacks. We assessed responses to LDV/SOF in a cohort of Black HIV/HCV coinfected persons. Retrospective chart reviews were conducted for Black, genotype 1 (GT1), HIV/HCV coinfected patients treated with LDV/SOF at 3 hospitals in Newark, NJ between January 2014 and July 2016. Data collected included demographics, HCV treatment history, treatment duration, and response. One hundred seventeen HIV/HCV coinfected Black patients started treatment with LDV/SOF but 5 had no follow-up data and 5 prematurely discontinued treatment (1 due to side effects). We included 107 HIV/HCV coinfected patients who completed LDV/SOF at all 3 sites. The study population was 65% male, median age 58 years, 26% had cirrhosis, and 78% had GT1a. Thirty-one percent were treatment experienced but none with prior NS5a treatment. At baseline, median CD4 count was 680 cells/mm(3), HIV viral load (VL) was <40 copies/mL in 94% and median HCV VL was 2,257,403 IU/mL. Twenty-nine percent of patients changed antiretroviral treatment before LDV/SOF treatment due to drug interactions. Six, 89, and 12 patients completed 8, 12, and 24 weeks of LDV/SOF, respectively. Overall sustained virologic response rate was 93% with 7 relapses. In this real-world cohort of Black, GT1, HIV/HCV coinfected patients, LDV/SOF had high sustained virologic response 12 weeks post completion of treatment rate of 93%. This data supports the overall high efficacy of LDV/SOF in a historically difficult-to-treat patient population.
format Online
Article
Text
id pubmed-7440318
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-74403182020-09-04 Hepatitis C virus treatment response to ledipasvir/sofosbuvir among patients coinfected with HIV and HCV: Real world data in a black population Banga, Jaspreet Nizami, Sobia Slim, Jihad Nagarakanti, Sandhya Portilla, Mario Swaminathan, Shobha Medicine (Baltimore) 4850 Treatment of hepatitis C virus (HCV) infection for patients with human immunodeficiency virus (HIV) has improved with direct acting antivirals. However, outcomes among Black persons treated with ledipasvir/sofosbuvir (LDV/SOF) may be inferior to non-Blacks. We assessed responses to LDV/SOF in a cohort of Black HIV/HCV coinfected persons. Retrospective chart reviews were conducted for Black, genotype 1 (GT1), HIV/HCV coinfected patients treated with LDV/SOF at 3 hospitals in Newark, NJ between January 2014 and July 2016. Data collected included demographics, HCV treatment history, treatment duration, and response. One hundred seventeen HIV/HCV coinfected Black patients started treatment with LDV/SOF but 5 had no follow-up data and 5 prematurely discontinued treatment (1 due to side effects). We included 107 HIV/HCV coinfected patients who completed LDV/SOF at all 3 sites. The study population was 65% male, median age 58 years, 26% had cirrhosis, and 78% had GT1a. Thirty-one percent were treatment experienced but none with prior NS5a treatment. At baseline, median CD4 count was 680 cells/mm(3), HIV viral load (VL) was <40 copies/mL in 94% and median HCV VL was 2,257,403 IU/mL. Twenty-nine percent of patients changed antiretroviral treatment before LDV/SOF treatment due to drug interactions. Six, 89, and 12 patients completed 8, 12, and 24 weeks of LDV/SOF, respectively. Overall sustained virologic response rate was 93% with 7 relapses. In this real-world cohort of Black, GT1, HIV/HCV coinfected patients, LDV/SOF had high sustained virologic response 12 weeks post completion of treatment rate of 93%. This data supports the overall high efficacy of LDV/SOF in a historically difficult-to-treat patient population. Wolters Kluwer Health 2020-03-13 /pmc/articles/PMC7440318/ /pubmed/32176039 http://dx.doi.org/10.1097/MD.0000000000019140 Text en Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0
spellingShingle 4850
Banga, Jaspreet
Nizami, Sobia
Slim, Jihad
Nagarakanti, Sandhya
Portilla, Mario
Swaminathan, Shobha
Hepatitis C virus treatment response to ledipasvir/sofosbuvir among patients coinfected with HIV and HCV: Real world data in a black population
title Hepatitis C virus treatment response to ledipasvir/sofosbuvir among patients coinfected with HIV and HCV: Real world data in a black population
title_full Hepatitis C virus treatment response to ledipasvir/sofosbuvir among patients coinfected with HIV and HCV: Real world data in a black population
title_fullStr Hepatitis C virus treatment response to ledipasvir/sofosbuvir among patients coinfected with HIV and HCV: Real world data in a black population
title_full_unstemmed Hepatitis C virus treatment response to ledipasvir/sofosbuvir among patients coinfected with HIV and HCV: Real world data in a black population
title_short Hepatitis C virus treatment response to ledipasvir/sofosbuvir among patients coinfected with HIV and HCV: Real world data in a black population
title_sort hepatitis c virus treatment response to ledipasvir/sofosbuvir among patients coinfected with hiv and hcv: real world data in a black population
topic 4850
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7440318/
https://www.ncbi.nlm.nih.gov/pubmed/32176039
http://dx.doi.org/10.1097/MD.0000000000019140
work_keys_str_mv AT bangajaspreet hepatitiscvirustreatmentresponsetoledipasvirsofosbuviramongpatientscoinfectedwithhivandhcvrealworlddatainablackpopulation
AT nizamisobia hepatitiscvirustreatmentresponsetoledipasvirsofosbuviramongpatientscoinfectedwithhivandhcvrealworlddatainablackpopulation
AT slimjihad hepatitiscvirustreatmentresponsetoledipasvirsofosbuviramongpatientscoinfectedwithhivandhcvrealworlddatainablackpopulation
AT nagarakantisandhya hepatitiscvirustreatmentresponsetoledipasvirsofosbuviramongpatientscoinfectedwithhivandhcvrealworlddatainablackpopulation
AT portillamario hepatitiscvirustreatmentresponsetoledipasvirsofosbuviramongpatientscoinfectedwithhivandhcvrealworlddatainablackpopulation
AT swaminathanshobha hepatitiscvirustreatmentresponsetoledipasvirsofosbuviramongpatientscoinfectedwithhivandhcvrealworlddatainablackpopulation